Journal of Cystic Fibrosis
Volume 9, Issue 4 , Pages 257-262, July 2010

Serum-surfactant SP-D correlates inversely to lung function in cystic fibrosis

  • Hanne Vebert Olesen

      Affiliations

    • Department of Pediatrics, Aarhus University Hospital, Skejby, 8200 Århus N, Denmark
    • Corresponding Author InformationCorresponding author. Pediatric Department A Aarhus University Hospital Skejby 8200 Aarhus N, Denmark. Tel.: +45 89 49 67 40; fax: + 45 89 49 60 23.
    • ,
  • Uffe Holmskov

      Affiliations

    • Medical Biotechnology Center, University of Southern Denmark, 5230 Odense M, Denmark
    • ,
  • Peter Oluf Schiøtz

      Affiliations

    • Department of Pediatrics, Aarhus University Hospital, Skejby, 8200 Århus N, Denmark
    • ,
  • Grith Lykke Sørensen

      Affiliations

    • Medical Biotechnology Center, University of Southern Denmark, 5230 Odense M, Denmark

Received 31 January 2010; received in revised form 22 March 2010; accepted 29 March 2010.

Abstract 

Background

Cystic fibrosis (CF) affects the lungs causing infections and inflammation. Surfactant protein D (SP-D) is an innate defense lectin primarily secreted in the lungs. We investigated the influence of the SP-D Met11Thr polymorphism on CF lung function; and serum SP-D as a marker for CF lung disease.

Methods

For 107 CF patients (73 children, and 34 adults) serum SP-D and SP-D Met11Thr genotype were available. Leukocyte count was obtained for a subset of patients. Lung function was measured as forced expiratory volume in one second (FEV-1).

Results

Serum SP-D was increased in CF patients compared to healthy controls, positively correlated to leukocyte count, and negatively correlated to FEV-1. We found no correlation between SP-D Met11Thr genotype and FEV-1, and we found corresponding genotype frequencies in CF patients and in healthy controls.

Conclusion

Serum SP-D in CF patients was increased in parallel with leukocyte count and with reduced FEV-1 and may constitute an alternative biomarker for lung disease, in the clinical setting and in research.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1569-1993(10)00038-X

doi:10.1016/j.jcf.2010.03.011

Journal of Cystic Fibrosis
Volume 9, Issue 4 , Pages 257-262, July 2010

Article Tools

* Image Usage & Resolution